Structure Pharma (GPCR): Price to Sales

Corporate company logo of Structure Pharma (GPCR)

Structure Therapeutics (GPCR) aims to develop oral treatments for diabetes and obesity, banking on the success of GSBR-1290 or an acquisition by industry behemoths. The shift in the price-to-sales ratio clearly demonstrates the market reaction to news, where represents the current level of the metric. Development relies on the expertise of elite biologists, while innovation is funded through the gradual drawdown of existing capital.

Structure Therapeutics Inc. - GPCR P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Structure Pharma (GPCR)

- current price and projected stock value:
Price Chart structuretx.com|GPCR - Price Target Chart
- stock exchange capitalization data:
Market Value Structure Pharma|GPCR - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Structure Therapeutics|GPCR - Book Capitalization|Market Capitalization to Book Value structuretx.com|GPCR - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Structure Therapeutics|GPCR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Structure Corp|GPCR - Company Debts|Debts to Net Assets Structure Pharma|GPCR - Company Long-Term Liabilities|Amount of Current Liabilities Structure Therapeutics|Intermediate Coverage Ratio structuretx.com
- financial results and valuation multiples details:
GPCR - Net Income|Projected Future Earnings Structure Therapeutics|GPCR - P/E Multiple|Projected Price to Earnings Structure Therapeutics Inc|GPCR - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Structure Pharma|GPCR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Structure Therapeutics|GPCR - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months structuretx.com|GPCR - Earnings growth in current year|Expected net earnings per share growth next year Structure Therapeutics
- issuer revenue and sales details:
GPCR - Company Sales|Company Future Revenue structuretx.com|GPCR - Market Cap to Revenue|Price to Expected Revenue Ratio Structure Pharma
Fundamental company analysis:GPCR, structuretx.com
Core merchandise of Structure Therapeutics

Investors use this ratio to determine the premium paid for a business by comparing the asset's market value with its actual ability to generate income. The capitalization-to-annual-revenue ratio in the P/S monitoring of Structure Therapeutics (GPCR) reflects market expectations for the commercialization of innovative drugs for the therapy of metabolic disorders, allowing for an assessment of the growth potential of Structure Therapeutics relative to its current financial results.

Who Structure Therapeutics competes with

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|Price-to-Revenue Ratio 89bio, Inc. ETNB|Price-to-Revenue Coefficient agios.com (AGIO)|MDXG: Market Cap to Revenue|Rezolute Inc - Market Cap to Sales Volume|Lexicon Pharma (LXRX) - Price-to-Revenue Ratio|MBX Corp - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ALT|P/S Multiple aardvarktherapeutics.com|P/S Multiple SGMT|Market Cap to Revenue BioAge Labs BIOA|Biomea - Market Cap to Revenue|Market Cap to Sales Volume QNCX (Quince Therapeutics Inc)|GUTS: Market Cap to Revenue|VTVT - P/S Multiple|agapeatpgroup.com (ATPC) - Price-to-Revenue Ratio|Pluri - Market Capitalization-to-Revenue Ratio|SYBX (Synlogic Inc.) - P/S Multiple|Price to Sales Lipocine Corporation LPCN|Market Cap to Revenue MTNB (Matinas BioPharma)|SPRB (sprucebiosciences.com) - Market Capitalization-to-Revenue Ratio|Galecto - Market Cap to Revenue|Market Cap to Sales Volume CTCX (Carmell Corp.)|Lumos Pharma Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio ONVO (Organovo Corp)|RDUS: P/S Multiple